

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 38/13, 39/395, 48/00, 49/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/43030</b> <b>(43) International Publication Date:</b> 27 July 2000 (27.07.00)
<b>(21) International Application Number:</b> PCT/US00/01553 <b>(22) International Filing Date:</b> 21 January 2000 (21.01.00)  <b>(30) Priority Data:</b> 60/116,845 22 January 1999 (22.01.99) US  <b>(71) Applicant (for all designated States except US):</b> FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KOBAYASHI, Masakazu [JP/US]; 3100 Lexington Lane #108, Glenview, IL 60025 (US). JIANG, Hongsi [CN/US]; 3026 Old Glenview Road, Wilmette, IL 60091 (US). YANG, Xiu-Fen [CN/US]; 21 Glenview Road, Glenview, IL 60025 (US).  <b>(74) Agents:</b> LARCHER, Carol et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).	<b>(81) Designated States:</b> BR, CA, CN, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> METHOD OF SUPPRESSING ONGOING ACUTE ALLOGRAFT REJECTION		
<b>(57) Abstract</b>  The present invention provides a method of suppressing ongoing acute allograft rejection. In one embodiment, the method comprises administering to a host experiencing ongoing acute allograft rejection an IL10 inhibitor and an IL2 inhibitor in amounts effective to rescue the allograft from ongoing acute rejection. In another embodiment, the method comprises administering to a host experiencing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor, an IL10 inhibitor in an amount effective to rescue the allograft from ongoing acute rejection.		